Immunotherapy for Advanced Liver Cancer

Summary

This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including subjects with macrovascular involvement and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with Child-Pugh stage A or B liver function. 150 subjects will be randomized 2:1 to AlloStim® immunotherapy vs Physician's Choice of Sorafenib, Lenvatinib or FOLFOX4.

Timeline

Start

2023-08-01

Primary completion

2026-11-01

Completion

2026-12-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor unable to fund”

Drugs

Indications